Toft Group Successfully Places Eduardo Dunayevich, MD as Vice President of Global Clinical Sciences with Greenwich Biosciences in Carlsbad, CA

Executive search firm Toft Group has placed Eduardo Dunayevich, MD, Vice-President of Global Clinical Sciences with Greenwich Biosciences in Carlsbad, CA.

Dr. Dunayevich is a board-certified psychiatrist with clinical development expertise within biotechnology and pharmaceutical companies. He recently served as Chief Medical Officer with Annexon Biosciences, with responsibility for clinical development, clinical operations and regulatory affairs across their neuroinflammation and intraocular therapy programs.

Previously, he held the role of Vice President and Global Product Lead, CNS at Takeda Pharmaceuticals. Prior to joining Takeda, Dr. Dunayevich was Executive Director and Global Development Leader, Neuroscience for Amgen. Dr. Dunayevich also spent 5 years with Orexigen Therapeutics as their Chief Medical Officer. Before that, he worked with Eli Lilly as a Medical Advisor in the Clinical Neuroscience Program Phase. Earlier in his industry career, Dr. Dunayevich served as Director of the Clinical Psychobiology Program, Psychobiology Inpatient Unit and Division of Clinical Trials of the Psychotic Disorders Research Program at the University of Cincinnati.
Dr. Dunayevich holds an MD from the University of Buenos Aires Medical School, Argentina.

About GW Pharmaceuticals plc and Greenwich Biosciences

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA approval for EPIDIOLEX (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older, pending DEA rescheduling. The Company has submitted a regulatory application in Europe for the adjunctive treatment of LGS and Dravet syndrome. The company continues to evaluate EPIDIOLEX in additional rare epilepsy conditions and currently has ongoing clinical trials in tuberous sclerosis complex (TSC) and infantile spasms (IS). GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a U.S. Phase 3 trial. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.